| 2.22 -0.15 (-6.33%) | 06-12 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 3.56 | 1-year : | 4.16 |
| Resists | First : | 3.04 | Second : | 3.56 |
| Pivot price | 1.88  |
|||
| Supports | First : | 1.31 | Second : | 0.25 |
| MAs | MA(5) : | 2.28 |
MA(20) : | 1.52 |
| MA(100) : | 1.17 |
MA(250) : | 1.37 |
|
| MACD | MACD : | 0.4 |
Signal : | 0.3 |
| %K %D | K(14,3) : | 71.1 |
D(3) : | 71.9 |
| RSI | RSI(14): 62.2 |
|||
| 52-week | High : | 3.04 | Low : | 0.25 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.[ SBFM ] has closed below upper band by 40.8%. Bollinger Bands are 472.9% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 21 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 2.46 - 2.47 | 2.47 - 2.48 |
| Low: | 2.18 - 2.2 | 2.2 - 2.21 |
| Close: | 2.19 - 2.22 | 2.22 - 2.24 |
Sunshine Biopharma, Inc. operates as a pharmaceutical entity and a provider of nutritional supplements, primarily dedicating its efforts to the research and development of novel anticancer therapies. A key pipeline candidate is Adva-27a, a GEM-difluorinated C-glycoside derivative of podophyllotoxin, designed to combat a broad spectrum of malignancies, including leukemia, lymphoma, testicular, lung, brain, prostate, bladder, colon, ovarian, and liver cancers. Notably, Adva-27a also demonstrates efficacy against multidrug-resistant cancer cells, encompassing pancreatic, breast, small-cell lung, and uterine sarcoma cells. The company is also progressing SBFM-PL4, a compound under development as an anti-coronavirus treatment. In addition to its drug development, Sunshine Biopharma markets a range of nutritional products, such as the Essential 9 tablet and the Essential Calcium-Vitamin D supplement, alongside other scientifically formulated dietary aids. A collaboration with the University of Georgia supports the ongoing advancement of SBFM-PL4 as an anti-coronavirus agent. The firm's headquarters are situated in Pointe-Claire, Canada.
Wed, 10 Jun 2026
Sunshine Biopharma Inc Stock Short Interest Rises to 68.28% - Quiver Quantitative
Mon, 08 Jun 2026
Sunshine Biopharma (NASDAQ: SBFM) approves Series C warrant provisions after reverse split - Stock Titan
Tue, 02 Jun 2026
SBFM Stock Jumps As Sunshine Biopharma Secures New Drug Approvals - StocksToTrade
Fri, 29 May 2026
Major holder of Sunshine Biopharma (NASDAQ: SBFM) approves share and Series C warrant terms - Stock Titan
Fri, 29 May 2026
Sunshine Biopharma Announces Issuance of U.S. Patent 12,624,066 B2 Covering Novel Coronavirus Treatment Technology - Yahoo Finance
Fri, 29 May 2026
Why Sunshine Biopharma (SBFM) Stock Dropped After Hours Today - Benzinga
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Drug Manufacturers - Specialty & Generic
|
|
| Shares Out | 2 (M) |
| Shares Float | 5 (M) |
| Held by Insiders | 0.6 (%) |
| Held by Institutions | 16.8 (%) |
| Shares Short | 50 (K) |
| Shares Short P.Month | 13 (K) |
| EPS | -12.5 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 4.69 |
| Profit Margin | -17.1 % |
| Operating Margin | -17.3 % |
| Return on Assets (ttm) | -10.1 % |
| Return on Equity (ttm) | -27.4 % |
| Qtrly Rev. Growth | -9.2 % |
| Gross Profit (p.s.) | 7.22 |
| Sales Per Share | 21.9 |
| EBITDA (p.s.) | -2.62 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -6 (M) |
| Levered Free Cash Flow | -5 (M) |
| PE Ratio | -0.18 |
| PEG Ratio | 0 |
| Price to Book value | 0.47 |
| Price to Sales | 0.1 |
| Price to Cash Flow | -0.63 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|